Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
1.
Article in English | MEDLINE | ID: mdl-32984260

ABSTRACT

RNA binding proteins (RBPs) play a key role in genome regulation. Here we report the post-transcript regulation of IGF2BP3, which belongs to the insulin-like growth factor 2 mRNA binding protein family. We used iRIP-seq and RNA-seq to analyze the transcript regulation and alternative splicing on IGF2BP3 treated with overexpression cells and control. Overexpressed IGF2BP3 has broadly increased genes expression which involved in G-protein coupled receptor signaling pathway, positive regulation of cell proliferation, and signal transduction. IGF2BP3 regulated alternative splicing of multiple genes mainly clustered at response to hypoxia, negative regulation of transcription, and embryonic development. This study first provides alternative splicing analysis on transcription level of IGF2BP3 regulation, which laid the foundation for later research on IGF2BP3 critical functions.

2.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-459647

ABSTRACT

Primary seminal vesicle adenocarcinoma (PSVA) is an extremely rare disease without any unified diagnostic criterion. Differential diagnosis of PSVA from prostate cancer, colon cancer, and bladder cancer is necessary but difficult because of the lack of standard management. Radical resection is considered the mainstay of primary treatment that offers satisfactory prognosis. Most cases with PSVA are diagnosed at advanced stages because its early manifestation is nonspecific and it is rarely diagnosed in clinic. In this study, we described the case of a 52 year-old PSVA patient who was treated at the Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, in July 2012. The patient underwent local excision, with tumor residuals visible under the naked eye. The patient benefits from a six-cycle paclitaxel (175 mg/m2) therapeutic regimen combined with cisplatin (60 mg/m2), as well as pelvic modulated radiotherapy with a radiation dose of 60 Gy/30 F. At present, the patient is disease-free and undergoes regu-lar follow-up.

3.
Article in English | WPRIM (Western Pacific) | ID: wpr-635026

ABSTRACT

To preliminarily determine the appropriate dosage of carboplatin (CBP) at AUC of 5 mg.Ml(-1).min(-1) in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer (NSCLC). Thirty-five Chinese senile patients with NSCLC in advanced stage (III/IV) were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol+CBP, Gemzar+CBP and NVB+CBP. The dose of CBP was at 5 mg.mL(-1).min(-1) of area under the concentration-time curve (AUC). Side effects and quality of life were observed before and after the chemotherapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granulocytopenia was found in 47.9% (46/96) of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% (27/96) of the subjects. However, other side effects were slight. The mean score of quality of life (QOL), according to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg.mL(-1).min(-1) by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg.mL(-1).min(-1) by AUC may be too high for Chinese senile patients with non-small cell lung cancer.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Area Under Curve , Carboplatin/administration & dosage , Carboplatin/adverse effects , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy
4.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-284670

ABSTRACT

To preliminarily determine the appropriate dosage of carboplatin (CBP) at AUC of 5 mg·Ml-1·min-1 in the combination chemotherapy for Chinese senile patients with non-small cell lung cancer (NSCLC). Thirty-five Chinese senile patients with NSCLC in advanced stage (Ⅲ/Ⅳ) were given 96 cycles of combination chemotherapy. Chemotherapy schedules included Taxol+CBE Gemzar+CBP and NVB+CBP. The dose of CBP was at 5 mg·mL-1·min-1 of area under the concen- tration-time curve (AUC). Side effects and quality of life were observed before and after the chemo- therapy. Myelosuppression was severe and commonly observed. Grade 3/4 of granuiocytopenia was found in 47.9% (46/96) of the patients and grade 3/4 of thrombocytopenia was noted in 28.1% (27/96) of the subjects. However, other side effects were slight. The mean score of quality of life (QOL), ac- cording to the criteria of QOL for Chinese cancer patients had reduced 6.8. At 5 mg·mL-1·min-1 by AUC, the hematological toxicity of CBP was severe and it had some negative effects on the QOL. The administration of CBP at 5 mg·mL-1·min-1 by AUC may be too high for Chinese senile patients with non-small cell lung cancer.

5.
Article in Chinese | WPRIM (Western Pacific) | ID: wpr-571634

ABSTRACT

Objective To evaluate the efficacy and the toxicity of 89Strontium( 89 Sr) radionuclide therapy for the senile patients with bone metastatic cancer, and study the effects of 89 Sr on the image of bone metastasis, and to assess the utility of 89 Sr treatment for the senile patients in rehabilitation. Methods The effect on pain relief and the side effects of 27 senile patients with bone metastatic cancer were observed. The bone SPECT image was compared between those before and after the treatment, blood routine and blood biochemistry was tested. Results The total response rate was 70.4%, while the response rate of bone metastasis originated from prostatic cancer and breast cancer was 78.9%. A few metastasis sites in bone image disappeared or the concentration in the image became weak. A mild reversible harm to bone marrow function was the main side effect. 89 Sr had a little effect on blood biochemistry. Conclusion Radionuclide therapy with 89 Sr was an effective and well-tolerated method for the senile patients with bone metastatic cancer, which was a novel approach for pain-relief and rehabilitation of senile patients with bone metastatic cancer.

SELECTION OF CITATIONS
SEARCH DETAIL
...